FGF21 decreases plasma triglycerides (TGs) in rodents and humans; however, the underlying mechanism or mechanisms are unclear. In the present study, we examined the role of FGF21 in production and disposal of TG-rich lipoproteins (TRLs) in mice. Treatment with pharmacological doses of FGF21 acutely reduced plasma non-esterified fatty acids (NEFAs), liver TG content, and VLDL-TG secretion. In addition, metabolic turnover studies revealed that FGF21 facilitated the catabolism of TRL in white adipose tissue (WAT) and brown adipose tissue (BAT). FGF21-dependent TRL processing was strongly attenuated in CD36-deficient mice and transgenic mice lacking lipoprotein lipase in adipose tissues. Insulin resistance in diet-induced obese and ob/ob mice shifted FGF21 responses from WAT toward energy-combusting BAT. In conclusion, FGF21 lowers plasma TGs through a dual mechanism: first, by reducing NEFA plasma levels and consequently hepatic VLDL lipidation and, second, by increasing CD36 and LPL-dependent TRL disposal in WAT and BAT.
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In Brief
Schlein et al. identify distinct mechanisms whereby FGF21 lowers plasma triglycerides in lean and obese mice. In lean mice, FGF21 reduces liver VLDL secretion and accelerates their disposal in WAT and BAT via CD36 and lipoprotein lipase. In obesity, FGF21-induced lipoprotein disposal shifts from white to brown fat.
INTRODUCTION
Fibroblast growth factor-21 (FGF21) has emerged as a novel therapeutic agent for the treatment of type 2 diabetes and the metabolic syndrome, exhibiting beneficial effects on glucose homeostasis, lipid metabolism, and body weight (Gimeno and Moller, 2014) . The metabolic effects of FGF21 are conferred through the fibroblast growth factor receptor (FGFR)-1c together, with the co-receptor b-klotho (KLB) (Kurosu et al., 2007; Kharitonenkov et al., 2008; Ding et al., 2012; Foltz et al., 2012) . Adipose tissue is a target organ of FGF21 action, as demonstrated by studies using adipose tissue knockout of FGFR1 or KLB, where these mice were refractory to effects of pharmacological FGF21 administration on insulin sensitivity, glucose tolerance, and weight loss (Foltz et al., 2012; Adams et al., 2012; Ding et al., 2012) . Further support for a key role of adipose tissue was provided by studies showing that adiponectin is important for systemic metabolic effects of FGF21 (Lin et al., 2013; Holland et al., 2013) and by the finding that FGF21-dependent metabolic improvements are absent in lipodystrophic mice (Vé niant et al., 2012a) . In addition to adipose tissue, emerging evidence implicates an important role of FGF21 signaling in the CNS for the metabolic effects of FGF21 (Sarruf et al., 2010; Bookout et al., 2013; Owen et al., 2015) . KLB is expressed in mouse liver. However, there is little to no expression of FGFR1c in this tissue; therefore, it is unlikely that liver is a direct target tissue for FGF21 action (Kurosu et al., 2007; Fon Tacer et al., 2010) . Nevertheless, FGF21 treatment has significant impact on hepatic lipid metabolism in mice, including decreased lipogenic gene transcription (Xu et al., 2009a) and increased fatty acid oxidation (Badman et al., 2007; Fisher et al., 2014) .
One of the most consistent outcomes of pharmacological FGF21 administration is a robust decrease in plasma triglycerides (TGs), which was observed in both preclinical studies and humans (Kharitonenkov et al., 2005 (Kharitonenkov et al., , 2007 Gaich et al., 2013; Huang et al., 2013; Gimeno and Moller, 2014) . Like other metabolic effects, TG lowering was found to depend, at least in part, on FGF21 signaling in adipose tissue (Vé niant et al., 2012a; Adams et al., 2012; Lin et al., 2013) . However, the mechanism or mechanisms by which FGF21 decreases TGs remain unclear. Plasma steady-state TG levels reflect the production of TG-rich lipoproteins (TRLs) by both the liver (as very low density lipoproteins, or VLDLs) and the intestine (as chylomicrons), as well as the disposal of TRLs and their remnants in the periphery and liver (Williams, 2008) . The production and secretion of VLDLs is determined by the availability of liver TGs and cholesterol (Adiels et al., 2008) , while insulin acutely suppresses VLDL assembly and subsequent release into the circulation (Choi and Ginsberg, 2011) . Previous research has established that most fatty acids constituting VLDL-TGs are derived from adipose tissue (Barrows and Parks, 2006) . TRL catabolism in peripheral organs, most notably adipose tissues, heart, and muscle, is controlled by lipoprotein lipase (LPL). LPL rapidly hydrolyses TGs within TRLs, releasing free fatty acids. These are then taken up by the underlying tissues through facilitative transporters, in particular CD36 (Su and Abumrad, 2009 ). LPL activity is regulated in a complex fashion by protein modulators such as apoCII, apoAV, and angiopoietin-like proteins, as well as trans-endothelial transport mediated by glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein-1 (Kersten, 2014; Wang and Eckel, 2009) . LPL is regulated tissue specifically, diverting fatty acids-preferably to adipose tissue in the postprandial state and to skeletal muscle during exercise (Wang and Eckel, 2009; Kersten, 2014) .
After LPL-mediated lipolysis, TRL remnant particles, which still contain substantial amounts of TGs, are taken up by lipoprotein receptor-mediated endocytosis into the liver (Williams, 2008) . The paradigm that TG-rich remnants are generally taken up by the liver has been challenged . We found that brown adipose tissue (BAT) activated by cold exposure takes up not only fatty acids released by LPL but also a substantial number of lipoprotein particles, indicating that BAT can become a major organ of lipoprotein clearance. Moreover, CD36, which functions as a fatty acid transporter, lipoprotein receptor, and signaling molecule (Su and Abumrad, 2009) , plays a key role in this process .
In the present study, we explored the role of FGF21 in the metabolism of TRLs by investigating the production, as well as the disposal, of TRLs in mice. FGF21 acutely reduced VLDL-TG secretion from the liver and directed TRL particles and fatty acids into white adipose tissue (WAT) and BAT while diminishing lipid flux to non-adipose organs. Furthermore, we demonstrated that this disposal process is dependent on LPL and CD36. In obese, insulin-resistant states, FGF21 did not stimulate TRL disposal in WAT but efficiently promoted TRL catabolism in BAT. In conclusion, we provide novel mechanistic insights by which acute and chronic FGF21 administration decreases serum TGs independently of weight loss.
RESULTS

Acute Administration of FGF21 Decreases VLDL-TG Secretion
To determine whether VLDL secretion is altered by acute FGF21 administration in C57BL/6J mice, we used tyloxapol (an effective inhibitor of TRL disposal, preventing access by LPL to the TRL lipid core) (Schotz et al., 1957) with and without glucose gavage to mimic postprandial and fasting conditions, respectively ( Figure 1A ). Glucose gavage decreased the secretion of both cholesterol ( Figure 1B ) and TGs ( Figure 1C ) compared to saline, consistent with insulin-mediated suppression of VLDL secretion (Choi and Ginsberg, 2011) . FGF21 administered 2 hr before tyloxapol had a selective suppressing effect on TG secretion ( Figure 1C ) but not cholesterol secretion ( Figure 1B ), indicating reduced TG loading of VLDLs in FGF21-treated mice. Moreover, FGF21 reduced plasma non-esterified fatty acids (NEFAs) ( Figure 1D ) and reduced hepatic TG content ( Figure 1E ) and cholesterol content ( Figure 1F ). To compare acute versus chronic effects of FGF21 on hepatic lipids, we treated mice either acutely or chronically (10 days) with FGF21. Both acute and chronic FGF21 administration significantly decreased plasma NEFAs ( Figure 1G ) and liver TG content ( Figure 1H ) to a similar extent, whereas reduction of liver cholesterol was more pronounced after acute, compared to chronic, treatment ( Figure 1I ). The impact of FGF21 was preserved in the insulinresistant state, as FGF21 decreased VLDL-TG secretion in diet-induced obese (DIO) mice ( Figure 1J ).
Acute FGF21 Does Not Affect Liver DNL but Decreases Hepatic TRL Secretion by Stimulating Fatty Acid Uptake in WAT Consistent with reduction in liver cholesterol content ( Figures  1F and 1I ), acute and chronic FGF21 administration increased expression of the biliary cholesterol exporters Abcg5 and Abcg8 (Figure 2A ). Chronic FGF21 treatment (6 weeks) of DIO mice has been shown to decrease hepatic expression of de novo lipogenesis (DNL) enzymes (Xu et al., 2009a) . In our study of lean mice, acute FGF21 treatment did not significantly alter hepatic lipogenic gene expression, and only a modest trend for downregulation was observed for most DNL genes after chronic treatment ( Figure 2A ). Hepatic DNL was further investigated by in vivo labeling using 3 H 2 O and found to be unchanged by acute FGF21 treatment in mice, with or without prior glucose gavage ( Figure 2B ). To assess whether FGF21 has a direct effect on hepatic TRL secretion, we studied primary hepatocytes after labeling with 3 H-glycerol, which is predominantly used as a backbone for TGs and phospholipids and secreted with TRLs by the cells. Insulin suppressed TRL secretion, whereas incubation with NEFAs increased TRL secretion ( Figure 2C ), as expected (Choi and Ginsberg, 2011) . In contrast, FGF21 treatment did not affect TRL secretion, either alone or in combination with insulin and/or NEFAs ( Figure 2C ). Taken together, these results strongly suggested that the reduction of liver TG and TRL-TG secretion after acute FGF21 administration was not due to FGF21 directly acting on hepatocytes but rather was caused by FGF21 action on adipocytes. To address the latter hypothesis, we first checked whether FGF21 had a suppressive effect on adipocyte lipolysis. Acute FGF21 administration did not reduce the activating phosphorylation site Ser 563 of hormone-sensitive lipase in WAT ( Figure 2D ), a surrogate marker of lipolysis. Moreover, FGF21 treatment had no significant effect on NEFA release from primary adipocytes, whereas insulin suppressed and the b3-adrenergic agonist CL316,243 stimulated lipolysis ( Figure 2E ). To test whether FGF21 is involved in adipocyte fatty acid uptake, we performed an in vivo experiment using intravenous injection of radiolabeled NEFAs. Acute FGF21 administration stimulated the uptake of NEFAs into WAT depots of fasted mice, whereas it decreased NEFA uptake in liver and heart and did not exhibit a significant effect in BAT, skeletal muscle, or kidney. A similar outcome was observed when a glucose gavage was applied before tracer injection ( Figure 2F ).
Taken together, these data suggest that in lean and obese mice, FGF21 acutely reduces VLDL lipidation. We provide evidence that this effect is explained by stimulating fatty acid uptake in WAT, thereby limiting the fatty acid supply and ultimately TG loading in the liver, but not by direct FGF21 action on liver.
FGF21 Administration Increases Postprandial TRL Disposal in Adipose Tissue Depots Next, we asked whether FGF21, in addition to decreasing hepatic VLDL lipidation, modulates the peripheral disposal of TRLs. We treated lean C57BL/6J mice chronically (10 days) or acutely (2 hr) with FGF21 and performed a combined oral glucose and fat tolerance test (OGFTT), using 3 H-deoxyglucose ( 3 H-DOG) and 14 C-oleate-labeled triolein as tracers ( Figure 3A ). FGF21 treatment had no significant effect on body weight, food intake, or organ weights in these animals ( Figures S1A-S1C ). Plasma TG levels were significantly lower compared to those of control upon both acute and chronic administration of FGF21 (Figure 3B ). In contrast, plasma cholesterol was slightly lower only in chronically treated mice ( Figure 3C ). Acute FGF21 treatment decreased glucose excursion during OGFTT, whereas chronic treatment of FGF21 had no such effect on glucose ( Figure 3D ). Fasting insulin levels were significantly decreased in both chronically and acutely treated animals ( Figure 3E ). To determine whether the decrease in plasma TGs is caused by increased disposal, we measured uptake of 14 C-oleate (released by LPL) in various organs. Although plasma counts were unaltered (Figure S1D ), 14 C-oleate uptake was significantly increased upon acute or chronic administration of FGF21 in all adipose depots and kidney ( Figure 3F ). There was no effect of FGF21 on skeletal muscle, whereas FGF21 decreased 14 C-oleate uptake in both liver and heart ( Figure 3F ). Adipose tissue uptake was similar in acutely and chronically treated mice, with the exception of inguinal WAT (ingWAT), which exhibited higher uptake after chronic FGF21 administration (p = 0.015, acute versus chronic) and subscapular BAT (scBAT), which showed significant uptake only after chronic treatment. When expressed as a fold increase of 14 C-oleate uptake compared to control, WAT depots were more responsive than BAT depots ( Figure 3G ).
3 H-DOG uptake was moderately increased in gonadal WAT (gonWAT) after acute FGF21 treatment and in BAT depots after chronic treatment (Figures 3H and 3I) . The most profound increase of 3 H-DOG uptake was observed in heart upon both acute and chronic FGF21 administration ( Figure 3H) .
Consistent with previous studies demonstrating that FGF21 increases browning of WAT (Fisher et al., 2012) , we observed an increase of brown adipocyte markers such as uncoupling protein 1 (Ucp1) and deiodinase type 2 (Dio2) in ingWAT ( Figure 3J ) (G-I) Chronic versus acute FGF21 dosing experiment (n = 8 per group). Mice were subcutaneously injected for 10 days with either saline (mock) or FGF21 (chronic FGF21) or for 9 days with saline and then with FGF21 on the final day (acute FGF21). Plasma NEFAs (G), liver TGs (H), and liver Chol (I) were determined in blood and tissues harvested 4 hr after final injection and food withdrawal. (J) VLDL secretion experiment (according to A) performed in DIO mice (n = 5-6 per group) treated acutely with FGF21. Mean ± SEM, Student's t test, *p < 0.05 mock versus FGF21, + p < 0.05 ÀGlc-mock versus +Glc-mock.
but not in gonWAT ( Figure 3K ) of FGF21-treated mice. In contrast, in both ingWAT and gonWAT, FGF21 increased the expression of the FGF21-responsive transcription factor early growth response 1 (Egr1) (Fisher et al., 2010) and the glucose transporter Glut1, whereas the mRNAs of Glut4 and the TRL disposal molecules Lpl and Cd36 showed only minor changes in ingWAT ( Figure 3J ) and gonWAT ( Figure 3K ). Taken together, these data indicate that FGF21-mediated TRL disposal observed in both WAT depots is independent of the browning process detected only in ingWAT.
FGF21 Promotes TRL Particle Uptake into Adipose Tissue Depots
To determine whether FGF21 induces TRL particle uptake, as observed in BAT upon cold exposure , we performed a turnover study by intravenous injection of radiolabeled, recombinant TRLs (rTRLs). A single dose of FGF21 was followed by oral glucose load to mimic the postprandial state. Subsequently, we injected rTRLs containing 14 C-triolein used as a fatty acid label and 3 H-cholesterylether (CE) as a marker for the lipoprotein core. Organs were harvested 30 min after (E) Effect of insulin (50 nmol/l), FGF21 (250 nmol/l), and the beta-3 adrenergic agonist CL316,243 (50 nmol/l) on NEFA release from primary white adipocytes determined in triplicates.
(F) Organ uptake of 14 C-labeled oleate 10 min after intravenous injection in C57BL/6J mice (n = 6 per group). Glucose gavage and FGF21 administration were performed as described in Figure 1 . Mean ± SEM, Student's t test, *p < 0.05.
rTRL application ( Figure 4A ). FGF21 increased the uptake of 14 C-oleate ( Figure 4B ) into ingWAT and interscapular BAT (iBAT) and, in the case of 3 H-CE ( Figure 4D ) uptake, into gon-WAT. The fold increase in uptake of both labels compared to control ( Figures 4C and 4E ) was similar between iBAT and ingWAT. Lipoprotein uptake in kidney was increased and heart uptake was significantly decreased, whereas liver and skeletal muscle lipoprotein uptake was unaltered ( Figures 4B-4E ). The increased uptake of 3 H-CE indicated whole TRL particle uptake into WAT. This was confirmed by intravital microscopy (H and I) 3 H-DOG uptake in disintegrations per minute per organ (H) and fold (I).
(J and K) Normalized mRNA expression in ingWAT (J) and in gonWAT (K) in relation to control (mock). See also Figure S1 . rpWAT, retroperitoneal WAT; muscle, quadriceps muscle. Mean ± SEM, Student's t test, *p < 0.05 mock versus FGF21.
experiments, in which increased rTRLs containing fluorescent quantum dots (QD-TRLs) were found to be associated with WAT endothelia of FGF21-treated compared to mock-treated animals ( Figure 4F ). FGF21 lowers the blood steady-state plasma concentrations of lipids, which may influence organ uptake by competing with lipid tracers on the proteins mediating TRL disposal. To rule out such a confounding effect, we infused anesthetized, exsanguinated lean mice with a physiological buffer containing radiolabeled TRLs. Prior acute administration of FGF21 potentiated uptake of TRL-oleate into WAT depots but not the other organs studied ( Figure 4G ). Administration of the b3-adrenergic agonist CL316,243 additionally stimulated TRL uptake in BAT, consistent with increased TRL disposal in activated BAT.
CD36 Is Regulated by FGF21 and Is Important for Efficient FGF21-Dependent TRL Disposal in WAT
We have previously shown that CD36 is essential for coldinduced TRL disposal in BAT . To determine whether this protein also plays a role in FGF21-induced TRL disposal, we performed a turnover experiment using CD36-deficient (Cd36 À/À ) mice and littermates (wild-type, or WT) (Figure 5A ). Compared to WT, Cd36 À/À mice exhibited significantly (A-E) C57BL/6J mice were treated acutely with FGF21. Subsequently, radiolabeled rTRLs were intravenously injected to detect organ-specific fatty acid and particle uptake, respectively (n = 6-7 per group). lower basal uptake of TRL core label ( 3 H-CE) and fatty acid label ( 14 C-triolein) into BAT but not WAT depots, whereas increased basal uptake was observed in liver ( Figures 5B and 5C ). Acute treatment of WT mice with FGF21 increased TRL uptake into the WAT depots ( Figures 5B and 5C ). However, the TRL uptake response of WAT to FGF21 was attenuated in Cd36 À/À mice, and this effect was especially pronounced with regard to the 14 C-oleate tracer ( Figures 5B and 5C ). Fatty acid transport activity of CD36 has been demonstrated to be regulated by translocation from intracellular vesicles to the plasma membrane (Koonen et al., 2005) . To test the hypothesis that FGF21 mediates increased NEFA uptake by such CD36 translocation, we biotinylated surface proteins of primary adipocytes and investigated the plasma membrane abundance of CD36. Western blotting against CD36 detected two prominent, biotinylated bands at approximately 70 and 90 kDa. The 70 kDa band in particular, presumably representing an isoform with low glycosylation (Jochen and Hays, 1993) , was increased after treatment of the cells with FGF21 ( Figure 5D ). The increase of the 70 kDa band was significantly increased compared to H-CE organ uptake. (D) Plasma membrane (PM) localization of CD36 in primary white adipocytes 1 hr after treatment with PBS (À) or FGF21 (+, 250 nmol/l), determined by cell surface biotinylation, pull-down with streptavidin, and anti-CD36 western blot. Two prominent CD36 isoforms were detected (low glycosylation, 70 kDa; high glycosylation, 90 kDa). (E) PM abundance of CD36 quantified by normalization to actin after densitometric quantification of protein bands from two independent experiments. Mean ± SEM, Student's t test, *p < 0.05 mock versus FGF21, + p < 0.05 Cd36 À/À versus equally treated WT group. controls, as demonstrated by densitometric quantification ( Figure 5E ). Taken together, these data suggest that CD36 fatty acid transporter translocation is regulated by FGF21 and they show that CD36 is not essential yet is important for efficient, FGF21-induced TRL disposal into WAT depots.
LPL Mediates FGF21-Induced TRL Disposal
To investigate whether LPL is important for FGF21-induced TRL disposal in WAT, we first investigated FGF21 responses in mice deficient for apoAV, a major modulator of LPL activity . Lean apoAV-deficient (Apoa5
) and WT mice on the same genetic background (FVB) were treated acutely with FGF21. Subsequently, an OGFTT was performed ( Figure 6A ) to study postprandial nutrient flux. FGF21 increased the organ uptake of the 14 C-oleate tracer into ingWAT and gonWAT of FVB-WT mice ( Figure 6B ). Basal 14 C-oleate uptake in WAT depots was lower in Apoa5 À/À mice. However, FGF21 induction of oleate uptake upon FGF21 treatment was partially retained in WAT of Apoa5 À/À mice ( Figure 6B ). Similar results were found for 3 H-DOG ( Figure 6C ). To directly assess the role of LPL in FGF21-induced WAT uptake of TRLs, we performed an OGFTT in adipocyte-specific Lpldeficient (aLPL À/À ) mice and Cre-negative aLPL +/+ littermates ( Figures 6D and 6E ). In this model, Lpl mRNA is reduced up to 95% in adipose tissues but not in other organs (Bartelt et al., 2013) , and the expression, as well as the Cre-dependent downregulation, of Lpl is evident in the adipocyte fraction of WAT compared to stromavascular cells ( Figure S2 ). Without FGF21 treatment, uptake of 14 C-oleate into WAT depots was unaltered in aLPL À/À mice compared to littermates, whereas it was decreased in BAT ( Figure 6D ). However, FGF21-induced 14 Coleate uptake into WAT was clearly attenuated in aLPL À/À mice ( Figure 6D ), demonstrating that LPL is an important mediator of FGF21-induced TRL disposal in WAT. Adipocyte LPL deficiency had no significant effects on 3 H-DOG organ uptake (Figure 6E ). In summary, we provide evidence that LPL is important for FGF21-mediated TRL disposal in WAT.
FGF21-Dependent TRL Disposal Is Impaired in WAT, but Not BAT, Depots of Insulin-Resistant Mice Next, we tested whether the FGF21-mediated effects on TRL disposal observed in lean C57BL/6J mice were also present in obese, insulin-resistant mice. For this purpose, DIO and leptindeficient (ob/ob) C57BL/6J mice were acutely (2 hr) or chronically (10 days) treated with FGF21. Consistent with published data (Coskun et al., 2008) , chronic FGF21 treatment significantly lowered body weight, especially in DIO mice, associated with non-significant reducing effects on food intake and adipose tissue weights ( Figures S3A-S3J ). This observation was confirmed in DIO mice with another genetic background ( Figures S3K-S3P ). To determine postprandial glucose and lipid flux, we performed an OGFTT, identical in design to the studies using lean mice. One set of mice was housed at ambient temperature Mean ± SEM, Student's t test, *p < 0.05 mock versus FGF21, + p < 0.05 aLPL À/À versus equally treated WT control.
(22 C) and compared to mice at thermoneutrality (30 C), a condition with blunted BAT activity (Cannon and Nedergaard, 2004) . DIO mice housed at 22 C exhibited improved glucose tolerance ( Figure 7A ) and insulin lowering ( Figure 7C ) after treatment with FGF21. In contrast to lean mice, however, acute FGF21 treatment had no significant effect on either 14 C-oleate uptake (Figure 7D) or 3 H-DOG uptake ( Figure 7E ) into WAT or BAT depots.
Even chronic FGF21 treatment failed to increase 14 C-oleate uptake into WAT ( Figure 7D ). However, chronic FGF21 significantly increased uptake of 14 C-oleate into BAT depots, whereas liver uptake was reduced ( Figure 7D ). Leptin-deficient ob/ob mice subjected to OGFTT exhibited similar but generally more pronounced effects than DIO mice ( Figure S4 ). Insulin levels (Figure S4B) were more than 10-fold higher than those in DIO mice and more than 100-fold higher compared to lean mice, indicating more severe insulin resistance. Glucose tolerance ( Figure S4A ), as well as 14 C-oleate ( Figure S4C ) and 3 H-DOG ( Figure S4D ) disposal into BAT, were significantly increased after acute FGF21 treatment. Overall, the magnitude of 14 C-oleate uptake ( Figure S4C ) and 3 H-DOG disposal ( Figure S4D ) into BAT depots was more robust after chronic compared to acute treatment.
Taken together, at ambient temperature, the response to FGF21 was altered in both obesity models compared to lean mice. FGF21 had no or even a negative effect on TRL disposal into WAT depots, while TRL disposal into BAT was markedly increased, especially after chronic treatment.
To assess the mechanism underlying the blunted FGF21 response of TRL disposal in ingWAT of DIO mice, we determined ingWAT gene expression and found, compared to lean mice, lower responses to FGF21. The increase of Egr1, Ucp1, and Dio2 by FGF21 was not evident in DIO mice, whereas FGF21-dependent induction of Glut1 mRNA was preserved ( Figure S5A ). In iBAT of DIO mice, the FGF21-dependent induction of Egr1 was also blunted; however, Dio2 was significantly induced by FGF21 ( Figure S5B ). The observation that TRL disposal in BAT of DIO mice was highly responsive to FGF21, despite apparent adipose tissue FGF21 resistance (indicated by the lack of Egr1 induction) ( Figure S5B ), suggested that central FGF21 action was preserved in the DIO mice and that this conferred BAT stimulation. When we analyzed DIO mice kept at 30 C, a condition with very low sympathetic tone in BAT (Cannon and Nedergaard, 2004), we found that they exhibited an improvement of glucose tolerance and hyperinsulinemia similar to mice housed at ambient temperature (22 C) ( Figures 7A-7C ). In contrast, FGF21-induced TRL disposal in BAT, but not in other organs, was strongly attenuated at 30 C compared to 22 C ( Figure 7D ). The relative uptake of 14 C-oleate into the BAT depots, calculated as the percentage of total tracer uptake into organs, approached 50% in DIO mice kept at 22 C after chronic FGF21 treatment ( Figure S6C ) compared to 25% in DIO mice at 30 C ( Figure S6D ), which also exhibited a reduced fold response ( Figures S6G and  S6H) . In lean mice, thermoneutrality also led to blunted FGF21-mediated TRL uptake into BAT depots ( Figures S6A and S6B) , whereas TRL uptake in WAT depots of both lean and DIO mice was not significantly affected by housing at 30 C ( Figure S6 ). Uptake of 3 H-DOG into BAT was only mildly reduced under thermoneutral conditions ( Figure S7 ). Taken together, these data provide evidence that FGF21-dependent TRL disposal into BAT is centrally mediated and requires basal sympathetic activation of the organ.
DISCUSSION
In the present study, we provide novel mechanistic insights demonstrating that the well-established TG-lowering effect of FGF21 (Kharitonenkov et al., 2005 (Kharitonenkov et al., , 2007 Gaich et al., 2013; Huang et al., 2013; Gimeno and Moller, 2014) can be explained by increased disposal, as well as reduced production, of TRLs. The pronounced TRL disposal into adipose tissues, especially WAT in lean mice and BAT in obese mice, is consistent with the previously reported role of adipose tissue in mediating metabolic effects of FGF21, as demonstrated in experiments using adipose-specific FGFR1 and KLB knockout mice (Foltz et al., 2012; Adams et al., 2012; Ding et al., 2012) . In an interplay with hepatic insulin action (Emanuelli et al., 2014) , FGF21 effects on adipose tissue can also explain the observed suppression of VLDL-TG secretion, namely, through suppression of plasma NEFAs by insulin sensitization or direct FGF21 action on WAT (Li et al., 2009; Camporez et al., 2013; Lee et al., 2014) . Our data show that FGF21 stimulates NEFA uptake into WAT, which may be mediated by fatty acid transporters such as CD36 or fatty acid transporter protein-1 in adipocytes (Wu et al., 2006) . In line with this assumption, we observed a direct FGF21 stimulation of CD36 translocation to the plasma membrane of primary adipocytes. Thus, FGF21 may promote fatty acid uptake in adipocytes directly and/or indirectly through insulin sensitization.
In addition to fatty acid uptake, we demonstrate that LPL is a crucial factor for FGF21-dependent TRL disposal. Previous work has established that in the postprandial state, adipose tissue LPL is activated by insulin (Wang and Eckel, 2009; Kersten, 2014) . FGF21 administration confers systemic insulin sensitivity, including WAT (Camporez et al., 2013; Lee et al., 2014) , suggesting that improved adipose tissue insulin signaling caused by FGF21 is involved in LPL activation. However, the cross-talk of the FGF21 and insulin signaling pathways is still under investigation, and clearly more work is needed to understand the interplay of insulin and FGF21 signaling in the complex regulation of LPL production and maturation (Kersten, 2014) . In this context, the role of the LPL modulator apoAV might be even more complicated. Recently, it has been demonstrated that hepatic apoAV knockdown improves insulin sensitivity. This effect was attributed to decreased diacylglycerol-mediated activation of protein kinase C (PKC)ε and PKCq in liver and muscle (Camporez et al., 2015) . Thus, the lower FGF21-dependent TRL uptake into organs of Apoa5 À/À mice compared to FVB-WT mice could be explained by high insulin sensitivity already at basal conditions. FGF21 promotes not only the uptake of fatty acids generated by LPL-dependent TG hydrolysis on the surface of the endothelium but apparently also the endocytosis of TRL particles, as indicated by increased CE uptake and association of QD-TRLs with the vascular endothelium of WAT. Furthermore, comparison of Cd36 À/À and WT mice shows that, similar to cold-activated BAT , the surface receptor CD36 is important for FGF21-induced TRL disposal. In chronic FGF21 treatment studies, TG-lowering plateaus before body weight loss is maximal (Foltz et al., 2012; Vé niant et al., 2012b) , suggesting a potentially independent mechanism by which FGF21 is able to elicit this process. We observed a strong effect of a single FGF21 dose on TG metabolism and little additional effect of chronic treatment in lean C57BL/6J mice. This demonstrates that an impact of FGF21 on TRL metabolism does not require long-term adaptations such as browning of WAT (Fisher et al., 2012) . Supporting this view, a recent publication reported equally decreased plasma TG and NEFA concentrations in lean UCP1-deficient mice and WT controls after treatment with a long-acting FGF21 analog (Vé niant et al., 2015) . Another study reported that under DIO conditions, FGF21-induced TG lowering was blunted in Ucp1-deficient mice (Samms et al., 2015) , which is consistent with our results that show BAT is important for TRL disposal in DIO mice. In any event, FGF21-dependent WAT browning is dispensable for FGF21-dependent TRL disposal and can be regarded as a consequence of increased sympathetic outflow induced by FGF21 (Owen et al., 2014) .
Consistent with published data (Xu et al., 2009b) , we observed acute insulin sensitization and increased glucose tolerance by FGF21 in obese mice. Surprisingly, we discovered that the strong stimulating effect of FGF21 on TRL disposal in WAT was abolished in both DIO and ob/ob mice while TRL lipid uptake into BAT was increased. The mechanism underlying the lack of FGF21-dependent TRL uptake into WAT of obese mice is probably related to FGF21 resistance in obesity, a concept proposed previously (Fisher et al., 2010) . In line with this, we observed an impaired response of some genes (Egr1, Dio2, and Ucp1) to FGF21 in WAT of DIO. In BAT of DIO mice, gene expression of Dio2 was induced by FGF21, whereas that of Egr1 was not. Because Egr1 is a gene that rapidly responds to FGF21 (Fisher et al., 2010) and Dio2 is a downstream target gene of cyclic AMP/adrenergic signaling (Arrojo e Drigo et al., 2013) , it is tempting to speculate that BAT direct responsiveness to FGF21 is impaired and that FGF21 signaling in the CNS, potentiating sympathetic outflow (Owen et al., 2014) , is responsible for the increased TRL uptake in BAT of DIO mice. Consistent with this notion, we observed profoundly reduced TRL disposal in BAT when animals were housed at thermoneutrality, a condition characterized by low sympathetic tone (Cannon and Nedergaard, 2004 ). FGF21 signaling both in adipose tissues (Foltz et al., 2012; Adams et al., 2012; Ding et al., 2012; Vé niant et al., 2012a) and in the CNS (Sarruf et al., 2010; Bookout et al., 2013; Owen et al., 2014 ) is important for the metabolic effects of FGF21. We provide strong evidence that FGF21 action in these organs differentially contributes to FGF21-dependent TRL disposal under lean versus obese conditions. Future work with organ-specific KLB knockout mice will be necessary to unequivocally identify the signaling alterations causing altered FGF21-dependent TRL uptake in obesity. Combining these models with CD36 and LPL knockouts would be a promising approach, helping not only to tease apart the central versus the peripheral contributions of FGF21 but also to gain further mechanistic insights into FGF21-dependent TRL processing.
From a physiological point of view, the redirecting of lipids into energy-combusting BAT without further storage in WAT might contribute to the weight loss and insulin sensitization effects of FGF21 that we and others have observed (Xu et al., 2009a; Coskun et al., 2008) . Whether the FGF21-dependent TRL uptake observed in BAT of obese mice translates to obese humans needs to be determined. Humans have less BAT than mice when expressed as a percentage of body weight, and obese people tend to have even less BAT content (Betz and Enerbä ck, 2015) . However, a recent study indicates that human BAT efficiently burns fatty acids in vivo (Ouellet et al., 2012) and that fatty acid uptake into BAT is not impaired in overweight subjects with type 2 diabetes compared to young healthy subjects (Blondin et al., 2015) .
Furthermore, our data support the notion that FGF21 can improve metabolic health by reducing ectopic lipid accumulation and thus lipotoxicity in non-adipose organs. Anti-lipotoxicity effects of FGF21 have convincingly been demonstrated for liver (Fisher et al., 2014; Camporez et al., 2013) . In the current study, we demonstrated that FGF21 reduced TGs, whereas it increased glucose flux to heart. This effect on heart is probably indirect through substrate competition with adipose tissues, because a significant effect was only observed when both BAT and WAT showed increased TRL disposal. Although we did not investigate lipotoxicity in heart, the observed fuel switch points toward a potential, beneficial role of FGF21 in the treatment of the diabetic heart (van de Weijer et al., 2011) .
Taken together, our study reveals novel mechanisms by which FGF21 reduces postprandial TGs and facilitates fatty acid storage in adipose tissues. By promoting the uptake of fatty acids into adipose tissues without increasing adiposity, FGF21 has the potential to improve metabolic health by preventing lipid accumulation in non-adipose tissues.
EXPERIMENTAL PROCEDURES Animals
All experiments were performed with permission of the Animal Welfare Officers at University Medical Center Hamburg-Eppendorf. Fabp4-Cre 3 Lpl flox/flox (aLPL À/À ) mice (Bartelt et al., 2013) , Apoa5 À/À mice ,
Cd36
À/À mice, ob/ob mice, and controls were kept at standard housing conditions (22 C-24 C) on a chow diet. Mouse climate chambers (Memmert) were used to compare ambient temperature (22 C) and thermoneutral temperature (30 C). DIO C57BL/6J mice (age 18-22 weeks) and ob/ob mice (age 12 weeks)
were purchased from Jackson Laboratories. DIO mice were kept on a high-fat diet (Bio-Serv3282). Unless indicated otherwise, age-and weight-matched male mice (8-20 weeks) were used. Human recombinant FGF21 (1.5 mg/kg/ day; Pfizer) or the b3-adrenergic agonist CL316,243 (1 mg/kg) in 0.9% saline or saline only (mock) were injected subcutaneously in the morning after short-term fasting. This dose is close to maximum efficacy for both FGF21 and CL316,243, and for FGF21, it results in blood concentrations more than 100-fold above physiological values (Xu et al., 2009b) . Blood for EDTA plasma was collected from tail vein or by cardiac puncture of anaesthetized mice.
Metabolic Tracer Studies
For organ uptake studies, oleate containing 14 C-oleate tracer complexed to BSA or rTRLs labeled with 3 H-CE and 14 C-triolein were injected intravenously.
OGFTTs were conducted by oral gavage of rTRLs supplemented with 14 Coleate and 2-deoxy-D-[ 3 H]-glucose. For in vivo infusion, anesthetized mice were perfused via the left heart ventricle with 3 H-triolein-labeled TRLs. In all experiments, organs were harvested after systemic perfusion with PBS-heparin (10 U/ml) via the left heart ventricle. Tissues were homogenized for counting using Solvable (PerkinElmer). Disintegrations per minute per organ data were calculated by multiplying measured disintegrations per minute per milligram with tissue weights.
Gene Expression and Protein Analysis
Gene expression analysis was performed by TaqMan-based qPCR with normalization on the housekeeper mTbp. Protein lysates from WAT were generated using radioimmunoprecipitation assay buffer. For cell surface biotinylation, primary adipocytes were incubated with PBS or FGF21 followed by incubation with EZ Link Sulfo-NHS-SS-Biotin (Thermo Scientific). Unbound biotin was removed, and cell lysates were incubated with Streptavidin Magnetic Beads (Thermo Scientific). Biotinylated cell surface proteins were eluted with SDS sample buffer (Invitrogen). All samples were separated on 10% polyacrylamide gels for western blotting.
Hepatic Lipid Metabolism VLDL production was determined by measuring plasma cholesterol and TGs after tail vein injection of 100 ml tyloxapol (10% in saline). For quantification of hepatic DNL, 2 hr fasted mice were injected subcutaneously with saline or FGF21 (1.5 mg/kg). After 2 hr, 3 H 2 O was intraperitoneally injected; after an additional 2 hr, 3 H incorporation into de novo-synthesized hepatic total lipids was determined in liver lipid extracts. A subgroup of mice received a glucose gavage (2 g/kg) 30 min before 3 H 2 O administration. Lipids were quantified in liver extracts by standard procedures using colorimetric kits.
Blood Parameters
Plasma TGs or cholesterol and NEFAs were measured using kits from Roche and Wako, respectively. Insulin was determined with an ultra-sensitive rat insulin ELISA kit (Crystal-Chem). Glucose was measured in tail blood using Aviva AccuCheck glucose sticks (Roche).
Intravital Microscopy Imaging Studies
The fate of TRLs at tissue level was studied using confocal intravital microscopy (Nikon-A1R) of externalized gonWAT in anesthetized mice using QD-TRLs . In the study, 200 ml QD-TRLs were tail vein injected, and images were taken after 30 min.
Lipoprotein Secretion in Primary Hepatocytes
Primary hepatocytes were incubated overnight with 3 H-glycerol. Subsequently cells were incubated with FGF21 (250 nmol/l) and/or insulin (50 nmol/l) in the presence or absence of BSA complexed with oleate. Supernatants were harvested after 4 hr, total lipids were extracted, and 3 H-glycerol lipid incorporated into lipoproteins secreted into supernatants was determined.
In Vitro Lipolysis Assay in Primary White Adipocytes Stroma vascular cells were isolated from gonadal fat pads of 6-to 10-week-old mice, and adipogenic differentiation was performed. After 10 days of differentiation, cells were stimulated with PBS, FGF21 (250 nmol/l), CL316,243 (50 nmol/l), or insulin (50 nmol/l). NEFAs released into supernatants were quantified using a kit from Wako.
Statistical Analysis
Values are expressed as mean ± SEM. Significant differences between groups were evaluated with a two-tailed, unpaired Student's t test.
More experimental details are provided in the Supplemental Experimental Procedures. Lean C57Bl/6J mice on chow diet (see Fig.3 ) received 10 daily doses of FGF21 (chronic FGF21), 9 daily doses of saline and 1 dose of FGF21 on the final day (acute FGF21) or 10 daily doses of saline (mock). The final dose was delivered 2h before OGFT and 4h before necropsy (Fig.3A) . Body weight (A) and food intake (B) were measured every other day. Organ weights (C) and plasma 14 C-oleate (D) were measured at necropsy. MeanSEM; p-values mock vs FGF21 calculated using Student's T-test. Gene expression in ingWAT and iBAT from DIO mice. Gene expression normalized to housekeeper (Tbp) in ingWAT (A) and iBAT (B) of DIO mice receiving 10 daily doses of FGF21 (chronic FGF21), 9 daily doses of saline and 1 dose of FGF21 on the final day (acute FGF21) or 10 daily doses of saline (mock). The final dose was delivered 2h before OGFT and 4h before necropsy (Fig.3A) . All values are presented as meanSEM; p-values mock vs FGF21 calculated using student's T-test. 
